Form 4: Elevation Oncology CFO Tammy Furlong Reports Stock Transactions
SEC Form 4 Filing
Tammy Furlong, CFO of Elevation Oncology, reports the vesting of restricted stock units and associated tax withholding.
Summary
- On August 15, 2024, Tammy Furlong, the Chief Financial Officer of Elevation Oncology, Inc. (ELEV), reported transactions involving the company's common stock and restricted stock units (RSUs).
- Furlong acquired 300 shares of common stock upon the vesting of RSUs.
- Simultaneously, 89 shares were disposed of to cover tax obligations at a price of $0.722 per share.
- Following these transactions, Furlong directly owns 1,208 shares of Elevation Oncology common stock and 3,000 restricted stock units.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing related to stock transactions by a company insider. It doesn't inherently indicate positive or negative sentiment, but rather reflects standard compensation practices and legal requirements.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which is important for investor confidence and regulatory compliance.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they primarily reflect internal compensation adjustments and tax obligations.
Key Dates
| Date | Description |
|---|---|
| 08/15/2024 | Date of the reported transactions (RSU vesting and tax withholding). |
| 08/19/2024 | Date of signature of the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.